Prestige Biologics Decides on 90 Billion KRW Paid-in Capital Increase
Prestige Biologics announced on the 12th that it has decided to conduct a paid-in capital increase through a third-party allotment to raise 89,926,340,000 KRW for debt repayment funds.
The number of new shares is 15,916,168 common shares.
The issue price per new share is 5,650 KRW, and the scheduled listing date of the new shares is the 25th of next month.
Hot Picks Today
"I Wish I Could Sleep": Frozen Meals, Two Hours...
- The Quoted 800,000 Won, the Bill Was 5 Million... Bereaved Families of 'No-Funer...
- Science and ICT Ministry?Education Ministry Hold First Meeting of "AI Talent Dev...
- Tragedy in Luxury Apartment: Woman in Her 20s Found Dead, Suspect Identified
- "Never Hike Alone as a Woman" "Even Two Are at Risk"... Growing Fear of Crime on...
The third-party allotment target is Prestige Biopharma.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
